1
|
Ribeiro VST, Bail L, Ito CAS, de Andrade AP, Arend LNVS, Suss PH, Nogueira KDS, Walflor HSM, Faoro H, Kuczera LCSDM, Vicenzi FJ, Tuon FF. In vitro susceptibility to fosfomycin in clinical and environmental extended-spectrum beta-lactamase producing and/or ciprofloxacin-non-susceptible Escherichia coli isolates. Rev Inst Med Trop Sao Paulo 2024; 66:e5. [PMID: 38324871 PMCID: PMC10846478 DOI: 10.1590/s1678-9946202466005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 12/06/2023] [Indexed: 02/09/2024] Open
Abstract
Extended-spectrum beta-lactamase producing and ciprofloxacin-non-susceptible Escherichia coli are clinical and environmental issues. We evaluated the susceptibility profile of fosfomycin in non-susceptible E. coli isolated from urine and the environment. We measured the activity of fosfomycin against 319 and 36 E. coli strains from urine and environmental isolates, respectively, collected from rivers. Fosfomycin resistance profiles were investigated using the minimal inhibitory concentration (MIC), according to the Clinical and Laboratory Standards Institute (CLSI) and the European Committee for Antimicrobial Susceptibility Testing (EUCAST) guidelines. Antibiotic susceptibility testing revealed that 5% and 6.6% of urine samples were non-susceptible to fosfomycin according to CLSI and EUCAST guidelines, respectively. The fosfomycin MIC50/90 was 0.5/4 mg/L. Of the 36 E. coli isolates from river water, 11.1% and 13,8% were non-susceptible to fosfomycin according to CLSI and EUCAST, respectively (range ≤0.25 ≥512 mg/L). All the isolates with MIC ≥512 mg/L for fosfomycin showed the fosA3 gene. Fosfomycin resistance was more frequent in the environment than in clinical samples.
Collapse
Affiliation(s)
- Victoria Stadler Tasca Ribeiro
- Pontifícia Universidade Católica do Paraná, Escola de Medicina, Programa de Pós-Graduação em Ciências da Saúde, Laboratório de Doenças Infecciosas Emergentes, Curitiba, Paraná, Brazil
| | - Larissa Bail
- Pontifícia Universidade Católica do Paraná, Escola de Medicina, Programa de Pós-Graduação em Ciências da Saúde, Laboratório de Doenças Infecciosas Emergentes, Curitiba, Paraná, Brazil
- Universidade Estadual de Ponta Grossa do Paraná, Divisão de Microbiologia, Ponta Grossa, Paraná, Brazil
| | - Carmen Antonia Sanches Ito
- Pontifícia Universidade Católica do Paraná, Escola de Medicina, Programa de Pós-Graduação em Ciências da Saúde, Laboratório de Doenças Infecciosas Emergentes, Curitiba, Paraná, Brazil
- Universidade Estadual de Ponta Grossa do Paraná, Divisão de Microbiologia, Ponta Grossa, Paraná, Brazil
| | - Ana Paula de Andrade
- Pontifícia Universidade Católica do Paraná, Escola de Medicina, Programa de Pós-Graduação em Ciências da Saúde, Laboratório de Doenças Infecciosas Emergentes, Curitiba, Paraná, Brazil
| | - Lavinia Nery Villa Stangler Arend
- Pontifícia Universidade Católica do Paraná, Escola de Medicina, Programa de Pós-Graduação em Ciências da Saúde, Laboratório de Doenças Infecciosas Emergentes, Curitiba, Paraná, Brazil
- Laboratório Central do Estado do Paraná, São José dos Pinhais, Paraná, Brazil
| | - Paula Hansen Suss
- Pontifícia Universidade Católica do Paraná, Escola de Medicina, Programa de Pós-Graduação em Ciências da Saúde, Laboratório de Doenças Infecciosas Emergentes, Curitiba, Paraná, Brazil
| | | | | | - Helisson Faoro
- Fiocruz Paraná, Instituto Carlos Chagas, Laboratório de Biologia Celular, Curitiba, Paraná, Brazil
| | | | | | - Felipe Francisco Tuon
- Pontifícia Universidade Católica do Paraná, Escola de Medicina, Programa de Pós-Graduação em Ciências da Saúde, Laboratório de Doenças Infecciosas Emergentes, Curitiba, Paraná, Brazil
| |
Collapse
|
2
|
Grey B, Upton M, Joshi LT. Urinary tract infections: a review of the current diagnostics landscape. J Med Microbiol 2023; 72. [PMID: 37966174 DOI: 10.1099/jmm.0.001780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2023] Open
Abstract
Urinary tract infections are the most common bacterial infections worldwide. Infections can range from mild, recurrent (rUTI) to complicated (cUTIs), and are predominantly caused by uropathogenic Escherichia coli (UPEC). Antibiotic therapy is important to tackle infection; however, with the continued emergence of antibiotic resistance there is an urgent need to monitor the use of effective antibiotics through better stewardship measures. Currently, clinical diagnosis of UTIs relies on empiric methods supported by laboratory testing including cellular analysis (of both human and bacterial cells), dipstick analysis and phenotypic culture. Therefore, development of novel, sensitive and specific diagnostics is an important means to rationalise antibiotic therapy in patients. This review discusses the current diagnostic landscape and highlights promising novel diagnostic technologies in development that could aid in treatment and management of antibiotic-resistant UTIs.
Collapse
Affiliation(s)
- Braith Grey
- Peninsula Dental School, Faculty of Health, University of Plymouth, Plymouth, Devon, UK
| | - Mathew Upton
- School of Biomedical Sciences, Faculty of Health, University of Plymouth, Plymouth, Devon, UK
| | - Lovleen Tina Joshi
- Peninsula Dental School, Faculty of Health, University of Plymouth, Plymouth, Devon, UK
| |
Collapse
|
3
|
Rovelsky SA, Vu M, Barrett AK, Bukowski K, Wei X, Burk M, Jones M, Echevarria K, Suda KJ, Cunningham F, Madaras-Kelly KJ. Outpatient treatment and clinical outcomes of bacteriuria in veterans: A retrospective cohort analysis. ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY : ASHE 2022; 2:e168. [PMID: 36483437 PMCID: PMC9726514 DOI: 10.1017/ash.2022.285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 07/18/2022] [Accepted: 07/19/2022] [Indexed: 06/17/2023]
Abstract
OBJECTIVE To conduct a contemporary detailed assessment of outpatient antibiotic prescribing and outcomes for positive urine cultures in a mixed-sex cohort. DESIGN Multicenter retrospective cohort review. SETTING The study was conducted using data from 31 Veterans' Affairs medical centers. PATIENTS Outpatient adults with positive urine cultures. METHODS From 2016 to 2019, data were extracted through a nationwide database and manual chart review. Positive urine cultures were reviewed at the chart, clinician, and aggregate levels. Cases were classified as cystitis, pyelonephritis, or asymptomatic bacteriuria (ASB) based upon documented signs and symptoms. Preferred therapy definitions were applied for subdiagnoses: ASB (no antibiotics), cystitis (trimethoprim-sulfamethoxazole, nitrofurantoin, β-lactams), and pyelonephritis (trimethoprim-sulfamethoxazole, fluoroquinolone). Outcomes included 30-day clinical failure or hospitalization. Odds ratios for outcomes between treatments were estimated using logistic regression. RESULTS Of 3,255 cases reviewed, ASB was identified in 1,628 cases (50%), cystitis was identified in 1,156 cases (36%), and pyelonephritis was identified in 471 cases (15%). Of all 2,831 cases, 1,298 (46%) received preferred therapy selection and duration for cases where it could be defined. The most common antibiotic class prescribed was a fluoroquinolone (34%). Patients prescribed preferred therapy had lower odds of clinical failure: preferred (8%) versus nonpreferred (10%) (unadjusted OR, 0.74; 95% confidence interval [CI], 0.58-0.95; P = .018). They also had lower odds of 30-day hospitalization: preferred therapy (3%) versus nonpreferred therapy (5%) (unadjusted OR, 0.55; 95% CI, 0.37-0.81; P = .002). Odds of clinical treatment failure or hospitalization was higher for β-lactams relative to ciprofloxacin (unadjusted OR, 1.89; 95% CI, 1.23-2.90; P = .002). CONCLUSIONS Clinicians prescribed preferred therapy 46% of the time. Those prescribed preferred therapy had lower odds of clinical failure and of being hospitalized.
Collapse
Affiliation(s)
- Suzette A. Rovelsky
- Pharmacy Service, Boise Veterans’ Affairs Medical Center, Boise, Idaho
- Pharmacy Service, White River Veterans’ Affairs Medical Center, White River Junction, Vermont
| | - Michelle Vu
- Center for Medication Safety (VA MedSAFE), Hines Veterans’ Affairs Medical Center, Chicago, Illinois
- Optum Life Sciences-HEOR, Eden Prairie, Minnesota
| | - Alexis K. Barrett
- Center for Medication Safety (VA MedSAFE), Hines Veterans’ Affairs Medical Center, Chicago, Illinois
| | - Kenneth Bukowski
- Center for Medication Safety (VA MedSAFE), Hines Veterans’ Affairs Medical Center, Chicago, Illinois
| | - Xiangming Wei
- Center for Medication Safety (VA MedSAFE), Hines Veterans’ Affairs Medical Center, Chicago, Illinois
| | - Muriel Burk
- Center for Medication Safety (VA MedSAFE), Hines Veterans’ Affairs Medical Center, Chicago, Illinois
| | - Makoto Jones
- George E. Wahlen Medical Center, Salt Lake City, Utah
| | - Kelly Echevarria
- Veterans’ Affairs Pharmacy Benefits Management, Hines Veterans’ Affairs Medical Center, Chicago, Illinois
| | - Katie J Suda
- Pittsburgh Veterans’ Affairs Medical Center, Pittsburgh, Pennsylvania
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Francesca Cunningham
- Center for Medication Safety (VA MedSAFE), Hines Veterans’ Affairs Medical Center, Chicago, Illinois
| | - Karl J Madaras-Kelly
- Pharmacy Service, Boise Veterans’ Affairs Medical Center, Boise, Idaho
- College of Pharmacy, Idaho State University, Meridian, Idaho
| | | |
Collapse
|
4
|
Piraux A, Hammoud R, Riou J, Lebdai S, Faure S. Assessment of the Compliance of Cystitis Management According to French Recommendations through the Analysis of Prescriptions Collected in Community Pharmacies. Antibiotics (Basel) 2022; 11:antibiotics11070976. [PMID: 35884230 PMCID: PMC9312117 DOI: 10.3390/antibiotics11070976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2022] [Revised: 07/13/2022] [Accepted: 07/18/2022] [Indexed: 02/01/2023] Open
Abstract
Urinary tract infections, especially cystitis, are common infections; they are the second most prevalent cause of antibiotic prescriptions in community pharmacies. To reduce antimicrobial resistance, guidelines are revised regularly. This study aims to assess compliance between prescriptions collected in community pharmacies and French cystitis guidelines. A treatment is considered compliant if the nature, dosage, and duration of the antibiotics are correct. Only women aged 18–65 years with a diagnosis of cystitis were eligible. The participation of 16 pharmacies resulted in 303 prescriptions. Most infections were classified as uncomplicated cystitis (79.2%), general practitioners were the prescribers in more than 9 out of 10 cases, and fosfomycin trometamol was the antibiotic dispensed for 1 in 2 women. An average compliance of 66% was observed, but with disparities according to the type of cystitis. Two-thirds of cases of uncomplicated cystitis and recurrent cystitis followed the recommendations, whereas only 15% of cystitis cases that were at risk of complication did so. The inclusion of a urine examination in uncomplicated cystitis decreased the overall compliance rate to 5.8%. These results show the essential role played by pharmacists; they are the last line of defence before dispensing antibiotics. They must know the recommendations in order to apply them.
Collapse
Affiliation(s)
- Arthur Piraux
- University of Angers, Inserm, CNRS, MINT, SFR ICAT, F-49000 Angers, France;
- Correspondence:
| | - Ramy Hammoud
- Methodology and Biostatistics Department, University of Angers, F-49000 Angers, France;
| | - Jérémie Riou
- University of Angers, Inserm, CHU Angers, CNRS, MINT, SFR ICAT, F-49000 Angers, France;
| | - Souhil Lebdai
- Department of Urology, Angers University Hospital, F-49000 Angers, France;
| | - Sébastien Faure
- University of Angers, Inserm, CNRS, MINT, SFR ICAT, F-49000 Angers, France;
| |
Collapse
|